Next-generation DES: the COMBO dual therapy stent with Genous endothelial progenitor capturing technology and an abluminal sirolimus matrix. (March 2014)

• Record Type: Journal Article
• Authors: Woudstra, Pier; de Winter, Robbert J; Beijk, Marcel A
• Is Part Of: Expert review of medical devices. Volume 11:Number 2(2014)
• Page Start: 121
• Page End: 135
• Publication Date: 2014-03
• Subjects: endothelial progenitor cells -- percutaneous coronary intervention -- restenosis -- sirolimus -- stent -- stent thrombosis; Medical instruments and apparatus -- Periodicals; 610.28
• DOI: 10.1586/17434440.2014.882046
• Languages: English
• ISSNs: 1743-4440

Abstract

Abstract : In contrast to the use of cytotoxic or cytostatic drugs, a 'pro-healing' approach may have an effect that is beneficial on clinical outcomes. The endothelial progenitor cell capturing stent (ECS) technology accelerates re-endothelialization after implantation in animal models and in the human arteriovenous shunt model. Several clinical studies have shown its safety in non-complex lesions. However, in the prevention of in-stent restenosis in complex lesions, the ECS is less effective compared with drug-eluting stents. The novel COMBO dual therapy stent is the first stent to combine accelerated endothelial coverage and control of neo-intimal proliferation using a pro-healing technology with an abluminal elution of sirolimus. In the randomized REMEDEE trial, the COMBO dual therapy stent showed similar angiographic and clinical outcomes compared to the paclitaxel-eluting stent. The REMEDEE-OCT study showed equal vascular healing as assessed by optical coherence tomography of the COMBO dual therapy stent compared to the Xience-V stent.